Phelps Brand Welcomes World Champion Swimmer Penny Oleksiak as Global Brand Ambassador
8.10.2020 18:00:00 EEST | Business Wire | Press release
Phelps Brand today announced Canada’s youngest World Champion swimmer Penny Oleksiak is joining the team as an official global ambassador. As part of the Phelps Team, Oleksiak will train and compete utilizing the industry-leading range of products from training equipment to performance swim suits, including the FINA-approved Matrix Technical suit, which is available now to consumers worldwide at www.michaelphelps.com.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005297/en/
Michael Phelps welcomes World Champion swimmer Penny Oleksiak to the Phelps Brand. Photo courtesy of Phelps Brand.
Oleksiak, a World Champion swimmer and Olympic-record holder, has been tapped as the face of the Matrix campaign, the Phelps Brand’s first new product launch in 2020. As part of the Phelps Team, Oleksiak (CAN) will help advance the brand globally alongside the growing roster of elite athletes including World Champion and American-record holder Chase Kalisz (USA), two-time Olympian Georgia Davies (UK), French-record holder David Aubry (FRA) and Olympian Luca Pizzini (IT).
“I’m a big fan of Penny and what she’s been able to accomplish in the pool. I’m thrilled she is joining the Phelps Team as the first female global ambassador,” said Phelps. “Penny is a tremendous athlete who shares my passion for the sport and has already provided a lot of great insights for the Phelps Brand. Her personality, talent and confidence are huge assets for the entire swimming community.”
A four-time Olympic medalist and six-time World Championship medalist, Oleksiak is a force on Team Canada. As Canada’s youngest Olympic gold medalist, she holds the nation’s record for most Olympic medals at a single summer games. In her short career she has become known for her exciting come from behind victories, winning four Olympic and six World medals; and currently holds the Olympic Record for the 100 Freestyle.
“I am so excited to be part of the Phelps Team,” said Oleksiak. “I have looked up to Michael my entire career and now have the chance to learn from and work alongside him to bring an incredible experience and line of products to the swimming community. It really is a dream come true for me.”
The Phelps Brand, which originally launched as MP Brand in 2015, continues to develop technologically advanced racing and training suits for competitive swimmers under the direction of Michael Phelps and Hall of Fame coach Bob Bowman.
The first product to launch under the Phelps Brand is the Matrix Tech Suit, a top-of-the-line FINA-approved competitive tech suit created with propriety Exo-Core technology. The Matrix features both adaptive compression material to reduce muscle vibration and drag while ensuring maximum flexibility and freedom of movement. In addition, the Matrix includes a sustaining tape system for improved body position by utilizing front and back axis tape and cross-coordinating to improve length and position.
“Penny is a tremendous athlete and her unique experiences and insights will play a key role in helping inform the competitive swim product innovation in the Phelps Brand today,” said Andrew Gritzbaugh, General Manager of North America for Aqua Lung, the parent company of Phelps Brand and Aqua Sphere. “We’re very excited to welcome her to the team and look forward to supporting her in her future endeavors.”
To purchase Phelps Brand products go to www.michaelphelps.com.
About PHELPS BRAND
The Phelps Brand offers best-in-class, innovative swim products that are inclusive and accessible to a broad range of swimmers across the competitive swimming lifecycle. Combining Aqua Sphere’s global product design expertise and distribution with Michael Phelps’ and Coach Bob Bowman’s experiences at the highest levels of swim performance, the Phelps Brand features technical swim products leveraging proprietary technologies and performance enhancing designs. For more information, visit www.michaelphelps.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005297/en/
Contact information
Lindsay Goodson
lgoodson@aqualung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom